国内外新药进医保目录的比较研究及对我国相关政策建议  

Comparative study of the health insurance directory entrance procedure of new drug domestic and overseas and the suggestion on the relevant policy in China

作　　者：崔孟珣[1] 彭奕[2] 赵瑾[1] 房彤宇[1] 

机构地区：[1]军事医学科学院毒物药物研究所,北京100850 [2]军事医学科学院科技部,北京100850

出　　处：《药学实践杂志》2011年第3期226-228,共3页Journal of Pharmaceutical Practice

摘　　要：通过比较国外四大医疗保险模式,说明欧美等发达国家在将新药纳入报销目录上具有耗时短、评价科学、管理方便等特点,建议我国的医保目录工作应借鉴国际惯例和成功经验,加强对医保目录的科技支撑和组织协调、研究制定新药进入医保目录的扶持政策和措施,建立符合我国国情的医保目录制度。Four kinds of medical security system models in forgien countries were compared and evaluated.The health insurance list entrance procedrue of new drugs in forgien countries was rapid,scientific,and convenient in evaluation and adminstration.Our country should learn from the successful experiences to strengthen the scientific support and coordination of the selection of Medicare directory,study the supporting policies and measures of the entrance of new drugs into the health insurance directory,and establish medical insurance catalog system for national conditions.

关 键 词：新药 医保目录 比较研究 政策 

分 类 号：R95[医药卫生—药学]